Paper6371015
Developing new drugs for ovarian cancer: a challenging task in a changing reality.
Canetta RM and 1 other. J Cancer Res Clin Oncol, 1984. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. Developing new drugs for ovarian cancer: a challenging task in a changing reality. Papers, record 6371015. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6371015
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Ovarian Neoplasms | Major topic |
| Animals | |
| Cell Line | |
| Clinical Trials as Topic | |
| Combined Modality Therapy | |
| Disease Models, Animal | |
| Drug Evaluation | |
| Drug Evaluation, Preclinical | |
| Female | |
| Humans | |
| Mice | |
| Research Design | |
| Tumor Stem Cell Assay |
Source PubMed
References109
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 6131277 | JMS, successor to cisplatin in advanced ovarian carcinoma? | Lancet | 1983 | https://conductscience.org/library/papers/6131277 | PubMed |
| 2 | 6837681 | Soft agar colony formation assay for in vitro testing of sensitivity to chemotherapy of gynecologic malignancies. | Am J Obstet Gynecol | 1983 | https://conductscience.org/library/papers/6837681 | PubMed |
| 3 | 6846245 | Phase II study of maytansine in the treatment of advanced or recurrent adenocarcinoma of the ovary. A Gynecologic Oncology Group study. | Am J Clin Oncol | 1983 | https://conductscience.org/library/papers/6846245 | PubMed |
| 4 | 6447099 | Cyclophosphamide and floxuridine adjuvant chemotherapy for stage III and IV carcinoma of the ovary. | Gynecol Oncol | 1980 | https://conductscience.org/library/papers/6447099 | PubMed |
| 5 | 7011532 | Characterization of a murine ovarian reticulum cell sarcoma of histiocytic origin. | Cancer Res | 1981 | https://conductscience.org/library/papers/7011532 | PubMed |
| 6 | 329910 | A phase II clinical trial of prednimustine. Clinical screening cooperative group of E.O.R.T.C. | Biomedicine | 1977 | https://conductscience.org/library/papers/329910 | PubMed |
| 7 | 175277 | Management of ovarian carcinoma. Current concepts and future prospects. | N Engl J Med | 1976 | https://conductscience.org/library/papers/175277 | PubMed |
| 8 | 7201885 | Phase II trial of spirogermanium in advanced epithelial carcinoma of the ovary. | Cancer Treat Rep | 1982 | https://conductscience.org/library/papers/7201885 | PubMed |
| 9 | 6211231 | Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors. | Cancer Treat Rep | 1982 | https://conductscience.org/library/papers/6211231 | PubMed |
| 10 | 7200025 | Response to second line chemotherapy in ovarian cancer of epithelial origin. | Eur J Cancer Clin Oncol | 1981 | https://conductscience.org/library/papers/7200025 | PubMed |
| 11 | 404216 | Second trial drugs in ovarian cancer. | Gynecol Oncol | 1977 | https://conductscience.org/library/papers/404216 | PubMed |
| 12 | 626979 | Kinetics of growth and ectopic production of human chorionic gonadotropin by an ovarian cystadenocarcinoma cell line maintained in vitro. | Cancer Res | 1978 | https://conductscience.org/library/papers/626979 | PubMed |
| 13 | 7197985 | Use of high dose cis-dichlorodiammine platinum (II) (NSC--119875) following failure on previous chemotherapy for advanced carcinoma of the ovary. | Br J Obstet Gynaecol | 1981 | https://conductscience.org/library/papers/7197985 | PubMed |
| 14 | 7195308 | Update on in vitro testing on new drugs in ovarian cancer and melanoma. | Cancer Treat Rep | 1981 | https://conductscience.org/library/papers/7195308 | PubMed |
| 15 | 6896260 | A phase II trial of m-AMSA in the treatment of advanced gynecologic malignancies. | Am J Clin Oncol | 1982 | https://conductscience.org/library/papers/6896260 | PubMed |
| 16 | 7141920 | New agents in ovarian cancer. | Int J Radiat Oncol Biol Phys | 1982 | https://conductscience.org/library/papers/7141920 | PubMed |
| 17 | 6185891 | Megestrol acetate for the palliation of advanced ovarian carcinoma. | Obstet Gynecol | 1983 | https://conductscience.org/library/papers/6185891 | PubMed |
| 18 | 337083 | [The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)]. | Med Klin | 1977 | https://conductscience.org/library/papers/337083 | PubMed |
| 19 | 6458544 | High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy. | Gynecol Oncol | 1981 | https://conductscience.org/library/papers/6458544 | PubMed |
| 20 | 6402287 | The use of intravenous phenylalanine mustard followed by supervoltage irradiation in the treatment of carcinoma of the ovary. | Cancer | 1983 | https://conductscience.org/library/papers/6402287 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 3583641 | Activity of tricyclic nucleoside 5'-phosphate in model systems of human ovarian cancer. | Invest New Drugs | 1986 | https://conductscience.org/library/papers/3583641 | PubMed |
| 2347051 | A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas. | Cancer Chemother Pharmacol | 1990 | https://conductscience.org/library/papers/2347051 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6371015
GET https://conductscience.org/api/papers/v1/6371015/references?page=2